Ondine Biomedical Inc. (OBI.L)
GBp 8.13
(4.84%)
GBp 8.13
(4.84%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.65 Million | -16.34 Million | -12.54 Million | -6.33 Million | -7.55 Million | -10.08 Million |
| Net Income | -14.41 Million | -19.37 Million | -50.08 Million | -16.27 Million | -13.9 Million | -16.85 Million |
| Depreciation & Amortization | 587 Thousand | 493 Thousand | 514 Thousand | 1.22 Million | 1.21 Million | 922 Thousand |
| Deferred income taxes | - | - | 31.62 Million | 97 Thousand | -362 Thousand | 585 Thousand |
| Stock-based compensation | 640 Thousand | 1.44 Million | 4.06 Million | 8.45 Million | 5.51 Million | 5.12 Million |
| Change in working capital | -298 Thousand | 102 Thousand | 131 Thousand | -361 Thousand | -519 Thousand | 214 Thousand |
| Other non-cash items | 66 Thousand | 987 Thousand | 1.36 Million | 832 Thousand | 496 Thousand | -76 Thousand |
| Investing Cash Flow | -177 Thousand | -311 Thousand | -77 Thousand | 2.9 Million | -33 Thousand | -134 Thousand |
| Investments in PPE | -177 Thousand | -311 Thousand | -77 Thousand | -99 Thousand | -33 Thousand | -134 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | 3 Million | - | - |
| Financing Cash Flow | 3.78 Million | -275 Thousand | 41.9 Million | 3.82 Million | 6.57 Million | 10.16 Million |
| Debt repayment | -40 Thousand | - | -682 Thousand | -4.08 Million | -26 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -799 Thousand | - | - | - |
| Common Stock Issuance | 4.91 Million | - | 37.72 Million | - | - | - |
| Other Financing Activities | -1.08 Million | - | 5.65 Million | - | 6.6 Million | 10.16 Million |
| Accounts receivables | -142 Thousand | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 104 Thousand | -337 Thousand | -673 Thousand | 86 Thousand | -66 Thousand | -105 Thousand |
| Other working capital | -260 Thousand | 439 Thousand | 804 Thousand | -447 Thousand | -453 Thousand | 319 Thousand |
| Cash at beginning of period | 13.27 Million | 29.86 Million | 626 Thousand | 306 Thousand | 1.35 Million | 1.78 Million |
| Cash at end of period | 3.13 Million | 13.27 Million | 29.86 Million | 626 Thousand | 306 Thousand | 1.35 Million |
| Capital Expenditure | -177 Thousand | -311 Thousand | -77 Thousand | -99 Thousand | -33 Thousand | -134 Thousand |
| Effect of forex changes on cash | -89 Thousand | 335 Thousand | -45 Thousand | -76 Thousand | -43 Thousand | -378 Thousand |
| Net cash flow / Change in cash | -10.13 Million | -16.59 Million | 29.24 Million | 320 Thousand | -1.05 Million | -431 Thousand |
| Free Cash Flow | -13.83 Million | -16.65 Million | -12.61 Million | -6.43 Million | -7.58 Million | -10.21 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.51 Million | -3.84 Million | -14.41 Million | -4.75 Million | -19.37 Million | -6.9 Million |
| Depreciation & Amortization | 165.27 Thousand | 166.51 Thousand | 587 Thousand | 183.5 Thousand | 493 Thousand | 161.17 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 640 Thousand | - | 1.44 Million | - |
| Change in working capital | 11.05 Thousand | 482.84 Thousand | -298 Thousand | -658.81 Thousand | 102 Thousand | 611.18 Thousand |
| Other non-cash items | 383.51 Thousand | 32.65 Thousand | 66 Thousand | 1.3 Million | 987 Thousand | 448.31 Thousand |
| Investing Cash Flow | -5819.65 | 171.62 | -177 Thousand | -104.68 Thousand | -311 Thousand | -35.72 Thousand |
| Investments in PPE | -5820.89 | 171.62 | -177 Thousand | -104.68 Thousand | -311 Thousand | -35.72 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 3.07 Million | 2.36 Million | 3.78 Million | -126.94 Thousand | -275 Thousand | -77.45 Thousand |
| Debt repayment | - | -446.69 | -40 Thousand | -24.06 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.2 Million | 2.48 Million | 4.91 Million | - | - | - |
| Other Financing Activities | -130.36 Thousand | -125.63 Thousand | - | -102.88 Thousand | - | - |
| Accounts receivables | 52.37 Thousand | -134.38 Thousand | - | 50.53 Thousand | - | 8848.00 |
| Accounts payables | 172.26 Thousand | 517.3 Thousand | - | -765.3 Thousand | - | 751.24 Thousand |
| Inventory | -152.47 Thousand | -30.64 Thousand | 104 Thousand | 92.05 Thousand | -337 Thousand | -112.41 Thousand |
| Other working capital | 11.05 Thousand | 130.57 Thousand | - | -36.09 Thousand | 439 Thousand | -36.49 Thousand |
| Cash at beginning of period | 1.86 Million | 2.72 Million | 13.27 Million | 8.14 Million | 29.86 Million | 13.35 Million |
| Cash at end of period | 792.03 Thousand | 1.86 Million | 3.13 Million | 2.72 Million | 13.27 Million | 8.14 Million |
| Capital Expenditure | -5820.89 | 171.62 | -177 Thousand | -104.68 Thousand | -311 Thousand | -35.72 Thousand |
| Effect of forex changes on cash | - | - | -89 Thousand | -267.4 Thousand | 335 Thousand | 261.05 Thousand |
| Net cash flow / Change in cash | -1.07 Million | -859.2 Thousand | -10.13 Million | -5.41 Million | -16.59 Million | -5.21 Million |
| Free Cash Flow | -4.12 Million | -3.14 Million | -13.83 Million | -5.02 Million | -16.65 Million | -5.39 Million |
TLS
8706
7367
RFSL
6830
1094